CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 10, 2021—Qiagen and Inovio Pharmaceuticals have extended their partnership with a new agreement to develop liquid-biopsy–based companion diagnostic products based on next-generation sequencing technology to complement Inovio’s therapies.
The initial project focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, Inovio’s immunotherapy to treat advanced cervical dysplasia associated with human papillomavirus. The assay will be developed for use on the Illumina NextSeq 550Dx platform, the first development based on a partnership Qiagen and Illumina signed in October 2019.
Pages: 1 2